|
内容記述 |
Following the Fukushima Daiichi Nuclear Power Station accident, Japan improved its radiation emergency medical system to better respond to complex disasters. As part of this effort, six institutions, including the National Institutes for Quantum Science and Technology (QST), were designated as Advanced Radiation Emergency Medical Support Centers (AREMSC) in 2015. In April 2019, QST was further designated as the Core Center, taking a leading role.To strengthen its internal dose monitoring capabilities, QST built a dedicated facility at its Chiba site in March 2021. This facility, the Dose Assessment Building for Advanced Radiation Emergency Medicine, was established based on lessons from the 2017 internal contamination accident at the Oarai Research and Development Center. It focuses on bioassay techniques, especially for actinides.Over the past four years, the facility has made steady progress in internal dose assessment. Bioassay procedures for actinides have been optimized to improve chemical recovery and reduce processing time. New screening methods using small-volume urine samples and mass spectrometry have also been developed. For quality assurance, QST has participated in the PROCORAD international intercomparison since 2016. In recent years, it has received TOPLABO nominations in several categories. For in vivo monitoring, calibration methods reflecting radionuclide biokinetics are under development using a whole-body counter with three HPGe detectors. Lung monitoring protocols are also being refined. Additionally, performance tests of the portable thyroid monitor “I-Beetle,” launched in January 2024, are underway.This presentation will highlight these recent technical developments. |
